An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: A comparison with olanzapine

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Wu, Claire ^a   Yuen, Jessica ^a   Boyda, Heidi N ^a   Procyshyn, Ric M ^a,b   Wang, Cathy K ^a   Asiri, Yahya I ^a   Pang, Catherine C Y ^a   Honer, William G ^a,b   Barr, Alasdair M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Mental Health and Addictions Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LURASIDONE; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; ISOINDOLE DERIVATIVE; NEUROLEPTIC AGENT; THIAZOLE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; NONHUMAN; RAT; SINGLE DRUG DOSE; ANIMAL; COMPARATIVE STUDY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; ISOINDOLES; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES;

EID: 84907462257     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107116     Document Type: Article

References (72)

1. Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, et al. (2010) Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 71: 566-573.
2. Procyshyn RM, Su J, Elbe D, Liu AY, Panenka WJ, et al. (2014) Prevalence and patterns of antipsychotic use in youth at the time of admission and discharge from an inpatient psychiatric facility. J Clin Psychopharmacol 34: 17-22.
3. Honer WG, Thornton AE, Sherwood M, MacEwan GW, Ehmann TS, et al. (2007) Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. CNS Drugs 21: 699-714.
4. Chien IC, Hsu JH, Bih SH, Lin CH, Chou YJ, et al. (2008) Prevalence, correlates, and disease patterns of antipsychotic use in Taiwan. Psychiatry Clin Neurosci 62: 677-684.
5. Leung JY, Pang CC, Procyshyn RM, Barr AM (2014) Cardiovascular effects of acute treatment with the antipsychotic drug olanzapine in rats. Vascul Pharmacol.
6. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, et al. (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Jama 302: 1765-1773.
7. Baptista T, Serrano A, Uzcategui E, ElFakih Y, Rangel N, et al. (2011) The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela. Schizophr Res 126: 93-102.
8. Reynolds GP (2012) Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review. Clin Psychopharmacol Neurosci 10: 71-77.
9. Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC (2012) Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 135: 113-122.
10. Tse L, Procyshyn RM, Fredrikson DH, Boyda HN, Honer WG, et al. (2014) Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. Int Clin Psychopharmacol 29: 125-137.
11. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, et al. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80: 19-32.
12. Baptista T, ElFakih Y, Uzcategui E, Sandia I, Talamo E, et al. (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22: 477-495.
13. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, et al. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr Res.
14. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1: 1-93.
15. Hahn M, Chintoh A, Giacca A, Xu L, Lam L, et al. (2011) Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr Res 131: 90-95.
16. Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, et al. (2008) Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 33: 1633-1641.
17. Vidarsdottir S, de Leeuw van Weenen JE, Frolich M, Roelfsema F, Romijn JA, et al. (2010) Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab 95: 118-125.
18. Albaugh VL, Singareddy R, Mauger D, Lynch CJ (2011) A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One 6: e22662.
19. Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, et al. (2013) Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 62: 3232-3240.
20. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM (2010) Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 31: 484-497.
21. Baptista T, de Baptista EA, Lalonde J, Plamondon J, Kin NM, et al. (2004) Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog Neuropsychopharmacol Biol Psychiatry 28: 1305-1311.
22. Davey KJ, O'Mahony SM, Schellekens H, O'Sullivan O, Bienenstock J, et al. (2012) Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl) 221: 155-169.
23. Weston-Green K, Huang XF, Deng C (2012) Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. PLoS One 7: e33548.
24. Smith GC, Chaussade C, Vickers M, Jensen J, Shepherd PR (2008) Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 51: 2309-2317.
25. Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TK, et al. (2010) A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 34: 945-954.
26. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, et al. (2007) Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32: 289-297.
27. Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P, et al. (2009) Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model. Schizophr Res 108: 127-133.
28. Skrede S, Ferno J, Vazquez MJ, Fjaer S, Pavlin T, et al. (2012) Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol 15: 163-179.
29. Jassim G, Skrede S, Vazquez MJ, Wergedal H, Vik-Mo AO, et al. (2011) Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology (Berl).
30. Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, et al. (2009) Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl) 203: 73-84.
31. Weston-Green K, Huang XF, Deng C (2011) Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res 217: 337-346.
32. Boyda HN, Procyshyn RM, Tse L, Xu J, Jin CH, et al. (2013) Antipsychotic polypharmacy increases metabolic dysregulation in female rats. Exp Clin Psychopharmacol 21: 164-171.
33. Baptista T, Araujo de Baptista E, Ying Kin NM, Beaulieu S, Walker D, et al. (2002) Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res 957: 144-151.
34. Woo YS, Wang HR, Bahk WM (2013) Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat 9: 1521-1529.
35. Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, et al. (2014) Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, doubleblind, placebo-controlled study. Am J Psychiatry 171: 160-168.
36. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, et al. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382: 951-962.
37. Boyda HN, Procyshyn RM, Tse L, Wong D, Pang CC, et al. (2012) Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology 62: 1391-1400.
38. Boyda HN, Procyshyn RM, Tse L, Hawkes E, Jin CH, et al. (2012) Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatry Neurosci 37: 407-415.
39. Barr AM, Wu CH, Wong C, Hercher C, Topfer E, et al. (2013) Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats. Neuroscience 255: 147-157.
40. Barr AM, Fish KN, Markou A, Honer WG (2008) Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins. Eur J Neurosci 27: 2568-2574.
41. Barr AM, Young CE, Sawada K, Trimble WS, Phillips AG, et al. (2004) Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia. Eur J Neur-osci 20: 303-307.
42. Mather K (2009) Surrogate measures of insulin resistance: of rats, mice, and men. Am J Physiol Endocrinol Metab 296: E398-399.
43. Monzillo LU, Hamdy O (2003) Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr Rev 61: 397-412.
44. Bartoli E, Fra GP, Carnevale Schianca GP (2011) The oral glucose tolerance test (OGTT) revisited. Eur J Intern Med 22: 8-12.
45. Leiter LA, Ceriello A, Davidson JA, Hanefeld M, Monnier L, et al. (2005) Postprandial glucose regulation: new data and new implications. Clin Ther 27 Suppl B: S42-56.
46. Muniyappa R, Lee S, Chen H, Quon MJ (2008) Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294: E15-26.
47. Hughey CC, Hittel DS, Johnsen VL, Shearer J (2011) Hyperinsulinemic-euglycemic clamp in the conscious rat. J Vis Exp.
48. Boyda HN, Procyshyn RM, Pang CC, Hawkes E, Wong D, et al. (2013) Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. PLoS One 8: e53459.
49. Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, et al. (2008) Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 28: 494-499.
50. Park S, Sang Mee H, Il Sung A, Sung Hoon K (2010) Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them. J Psychopharmacol 24: 1105-1114.
51. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, et al. (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334: 171-181.
52. Simon V, van Winkel R, De Hert M (2009) Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 70: 1041-1050.
53. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305: 625-631.
54. Kapur S, Wadenberg ML, Remington G (2000) Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can J Psychiatry 45: 241-246.
55. Barr AM, Powell SB, Markou A, Geyer MA (2006) Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 51: 457-465.
56. Horiguchi M, Huang M, Meltzer HY (2011) Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl) 217: 13-24.
57. Huang M, Horiguchi M, Felix AR, Meltzer HY (2012) 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport 23: 436-440.
58. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, et al. (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 14: 36-51.
59. Martins PJ, Haas M, Obici S (2011) Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 59: 2418-2425.
60. Smith GC, Vickers MH, Shepherd PR (2011) Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch Physiol Biochem.
61. Victoriano M, Hermier D, Even PC, Fromentin G, Huneau JF, et al. (2009) Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats. Psychopharmacology (Berl) 206: 167-176.
62. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005) A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181: 80-89.
63. Patil BM, Kulkarni NM, Unger BS (2006) Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain. Eur J Pharmacol 551: 112-115.
64. Boyda HN, Procyshyn RM, Asiri Y, Wu C, Wang CK, et al. (2014) Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 48: 170-176.
65. Hahn MK, Chintoh A, Remington G, Teo C, Mann S, et al. (2014) Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model. Eur Neuropsychopharmacol 24: 448-458.
66. Barr AM, Procyshyn RM, Hui P, Johnson JL, Honer WG (2008) Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophr Res 100: 252-260.
67. von Hausswolff-Juhlin Y, Bjartveit M, Lindstrom E, Jones P (2009) Schizophrenia and physical health problems. Acta Psychiatr Scand Suppl: 15-21.
68. Boyda HN, Ramos-Miguel A, Procyshyn RM, Topfer E, Lant N, et al. (2014) Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats. Int J Neuropsychopharmacol 17: 77-90.
69. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, et al. (2012) Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 26: 733-759.
70. Ogasa M, Kimura T, Nakamura M, Guarino J (2013) Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharma-cology (Berl) 225: 519-530.
71. Citrome L, Weiden PJ, McEvoy JP, Correll CU, Cucchiaro J, et al. (2013) Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr: 1-10.
72. Girault EM, Alkemade A, Foppen E, Ackermans MT, Fliers E, et al. (2012) Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance. PLoS One 7: e43244.